These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

765 related articles for article (PubMed ID: 10077233)

  • 1. Specific inhibition of ADP-induced platelet aggregation by clopidogrel in vitro.
    Weber AA; Reimann S; Schrör K
    Br J Pharmacol; 1999 Jan; 126(2):415-20. PubMed ID: 10077233
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Ticlopidine and clopidogrel (SR 25990C) selectively neutralize ADP inhibition of PGE1-activated platelet adenylate cyclase in rats and rabbits.
    Defreyn G; Gachet C; Savi P; Driot F; Cazenave JP; Maffrand JP
    Thromb Haemost; 1991 Feb; 65(2):186-90. PubMed ID: 2053105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Disaggregatory effects of prostaglandin E1, amrinone and milrinone on platelet aggregation in human whole blood.
    Kikura M; Kazama T; Ikeda T; Sato S
    Platelets; 2000 Dec; 11(8):446-58. PubMed ID: 11177444
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Binding of [3H]-2-methylthio ADP to rat platelets--effect of clopidogrel and ticlopidine.
    Savi P; Laplace MC; Maffrand JP; Herbert JM
    J Pharmacol Exp Ther; 1994 May; 269(2):772-7. PubMed ID: 8182545
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Insights into the interpretation of light transmission aggregometry for evaluation of platelet aggregation inhibition by clopidogrel.
    Lordkipanidzé M; Pharand C; Palisaitis DA; Schampaert E; Diodati JG
    Thromb Res; 2009 Nov; 124(5):546-53. PubMed ID: 19419755
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Inhibition of platelet aggregation by prostaglandin E1 (PGE1) in diabetic patients during therapy with clopidogrel and aspirin.
    Kreutz RP; Nystrom P; Kreutz Y; Miao J; Kovacs R; Desta Z; Flockhart DA; Jin Y
    Platelets; 2013; 24(2):145-50. PubMed ID: 22385219
    [TBL] [Abstract][Full Text] [Related]  

  • 7. P2Y12, a new platelet ADP receptor, target of clopidogrel.
    Herbert JM; Savi P
    Semin Vasc Med; 2003 May; 3(2):113-22. PubMed ID: 15199474
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The in vivo pharmacological profile of CS-747, a novel antiplatelet agent with platelet ADP receptor antagonist properties.
    Sugidachi A; Asai F; Ogawa T; Inoue T; Koike H
    Br J Pharmacol; 2000 Apr; 129(7):1439-46. PubMed ID: 10742300
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clopidogrel (Plavix) and cardiac surgical patients: implications for platelet function monitoring and postoperative bleeding.
    Tanaka KA; Szlam F; Kelly AB; Vega JD; Levy JH
    Platelets; 2004 Aug; 15(5):325-32. PubMed ID: 15370104
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The greater in vivo antiplatelet effects of prasugrel as compared to clopidogrel reflect more efficient generation of its active metabolite with similar antiplatelet activity to that of clopidogrel's active metabolite.
    Sugidachi A; Ogawa T; Kurihara A; Hagihara K; Jakubowski JA; Hashimoto M; Niitsu Y; Asai F
    J Thromb Haemost; 2007 Jul; 5(7):1545-51. PubMed ID: 17456192
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Monitoring platelet inhibition after clopidogrel with the VerifyNow-P2Y12(R) rapid analyzer: the VERIfy Thrombosis risk ASsessment (VERITAS) study.
    Malinin A; Pokov A; Spergling M; Defranco A; Schwartz K; Schwartz D; Mahmud E; Atar D; Serebruany V
    Thromb Res; 2007; 119(3):277-84. PubMed ID: 16563469
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of clopidogrel, aspirin and both antiplatelet drugs on platelet function in patients with peripheral arterial disease.
    Jagroop IA; Matsagas MI; Geroulakos G; Mikhailidis DP
    Platelets; 2004 Mar; 15(2):117-25. PubMed ID: 15154604
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ticlopidine selectively inhibits human platelet responses to adenosine diphosphate.
    Cattaneo M; Akkawat B; Lecchi A; Cimminiello C; Capitanio AM; Mannucci PM
    Thromb Haemost; 1991 Dec; 66(6):694-9. PubMed ID: 1665598
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The thienopyridine ticlopidine selectively prevents the inhibitory effects of ADP but not of adrenaline on cAMP levels raised by stimulation of the adenylate cyclase of human platelets by PGE1.
    Gachet C; Cazenave JP; Ohlmann P; Bouloux C; Defreyn G; Driot F; Maffrand JP
    Biochem Pharmacol; 1990 Dec; 40(12):2683-7. PubMed ID: 2175608
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Assessment of clopidogrel responsiveness: measurements of maximum platelet aggregation, final platelet aggregation and their correlation with vasodilator-stimulated phosphoprotein in resistant patients.
    Gurbel PA; Bliden KP; Etherington A; Tantry US
    Thromb Res; 2007; 121(1):107-15. PubMed ID: 17400283
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of human blood platelet aggregation and the stimulation of nitric oxide synthesis by aspirin.
    Chakraborty K; Khan GA; Banerjee P; Ray U; Sinha AK
    Platelets; 2003; 14(7-8):421-7. PubMed ID: 14713511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Identification and biological activity of the active metabolite of clopidogrel.
    Savi P; Pereillo JM; Uzabiaga MF; Combalbert J; Picard C; Maffrand JP; Pascal M; Herbert JM
    Thromb Haemost; 2000 Nov; 84(5):891-6. PubMed ID: 11127873
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Inhibition of rat platelet aggregation by mycalolide-B, a novel inhibitor of actin polymerization with a different mechanism of action from cytochalasin-D.
    Sugidachi A; Ogawa T; Asai F; Saito S; Ozaki H; Fusetani N; Karaki H; Koike H
    Thromb Haemost; 1998 Mar; 79(3):614-9. PubMed ID: 9531051
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiplatelet action of R-99224, an active metabolite of a novel thienopyridine-type G(i)-linked P2T antagonist, CS-747.
    Sugidachi A; Asai F; Yoneda K; Iwamura R; Ogawa T; Otsuguro K; Koike H
    Br J Pharmacol; 2001 Jan; 132(1):47-54. PubMed ID: 11156560
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A clopidogrel-insensitive inducible pool of P2Y12 receptors contributes to thrombus formation: inhibition by elinogrel, a direct-acting, reversible P2Y12 antagonist.
    Haberstock-Debic H; Andre P; Mills S; Phillips DR; Conley PB
    J Pharmacol Exp Ther; 2011 Oct; 339(1):54-61. PubMed ID: 21730013
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.